Wells Fargo Keeps NovoCure at Equal-Weight, Cuts Target to $15
Wells Fargo maintained its Equal-Weight rating on NovoCure and lowered its price target to $15 from $20.
Wells Fargo maintained its Equal-Weight rating on NovoCure and lowered its price target to $15 from $20.